good idea...go ahead and place your order then :-)
so what's holding the price up? looking at the books the SP should be 0.05 on a good day.
a "steady as she goes" call....tracking slightly ahead of revs for the year. i think they are (rightly) being conservative on additional revs where they are still ramping up or have not received approval yet (but expect to). A little disappointing to see the UK lagging, that's a potentially big market to open. US...who knows, the FDA seem to be giving them the runaround ona perfeclty good, effective product. Very frustrating to see the FDA hold drugs back like this. I'm holding long...expect $15 in 12 months.
maybe and I'm way long on ctix...but i find these teaser PRs unprofessional....let the results speak for themselves and keep your trap shut until you have clinical data. this comes across as such BS...and hurts the credibility and brand.
i think institutions will start to sell sooner rather than wait.....they need to get what they can and if they all dump late in the year the SP will crash.....
that's a good point.....with all of the researchers they have not produced much over the years.....CF was actually bought when they acquired Aurora in San Diego. They really have not brought much to market from their internal research programs (over 25 years) and there is nothing close (next 4 years). CF is their ticket and it better work perfectly or they will be in trouble
the more I think about it the more i'm convinced that vrtrx will be eaten up once the bug guns see that the cf franchise is viable. it's a nice addition to a large portfolio. vrtx will be a one product company, their other assets either don't measure up to the competition or have been sitting on the shelf so long that they've been passed by (Incivek, 135, RA, flu) so i don't put a lot of value in the non-cf area and i don't think the big guys will either. plus their early development in cancer is 6-7 years away. so look for a good report-out on the cf drugs and big jump in sp; but that's the end of the road for them, the bug guys are waiting for the results and will pounce if they are positive.
mind you, if they are negative then vrtx is done....all the eggs are in one basket right now.
actually I think eltp looks good....will be holding for 2 years though...feel it can get to 2-3 bucks. am also in ctso and see a similar path ...possibly ramping up starting in the next week or two.
Roughly speaking the current market cap for vertex reflects most of the cf pipeline. Maybe a little more upside but not doubling any time soon. So, what's after cf? I know they are in cancer and huntingtons but would guess either of them is at least 4 yrs away. That's a big gap. I think their inability to progress RA, flu and HCV do not bode well for internal programs (remember, vertex bought cf when they bought aurora bio and that took about 10 years to get to market) they need to purchase to grow. Thoughts?
I think for the treatment areas being targeted by B, while the costs of hospital stays is a factor, the bigger factor from a Doctor's perspective is protecting the patient. So getting them a faster-acting, more effective treatment for what can be life-threatening infections (many of these patients will already be in a weakened condition) will be the main reason they would choose B. Gets them out of the hospital faster too (where most infections occur!).
Amazingly Zohydro was approved .....went against the advisory panel....very suspicious. FDA have no plans to review the decisions.....it will take public outrage/political pressure to reverse it.
I'm long, but I thought that very statement was a pathetic attempt to generate excitement. They need trial data and results at this point. In the meantime don't put out annoying statements like that. If you think the meds are good, then stay in the game..and ignore these silly PRs....the stock will move based on trials, not the CEO opinion.